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Abstract
Aims European Association of Cardiovascular Imaging/Heart Failure Association Cardiac Oncology Toxicity Registry was
launched in October 2014 as a European Society of Cardiology multicentre registry of breast cancer patients referred to
imaging laboratories for routine surveillance, suspected, or conﬁrmed anticancer drug-related cardiotoxicity (ADRC). After a
pilot phase (1 year recruitment and 1 year follow-up), some changes have been made to the protocol (version 1.0) and
electronic case report form.
Methods and results Main changes of the version 2.0 concerned exclusion criteria, registry duration, and clariﬁcation of the
population characteristics. Breast cancer radiotherapy has been removed as an exclusion criterion, which involves now only
history of a pre-chemotherapy left ventricular dysfunction. The period for long-term registry recruitment has been reduced
(December 2017), but the target study population was extended to 3000 patients. The characteristics of the population are
now better deﬁned: patients seen in an imaging lab, which will include patients undergoing chemotherapy with associated
targeted therapy or no targeted therapy, at increased risk of ADRC. In total, 1294 breast cancer patients have been enrolled,
and 783 case report forms locked from October 2014 to November 2016. Of these, 481 (61.4%) were seen at ﬁrst evaluation
and 302 (38.6%) while on oncologic treatment with anticancer drugs. Fifty-two patients (17.2%) were not in targeted
therapies, 191 (63.3%) were ongoing targeted therapy, and 59 (19.5%) had completed it. Twenty-three (2.9%) patients had
a suspected diagnosis and 35 (4.5%) a conﬁrmed diagnosis of ADRC. Arterial hypertension was the most prevalent
cardiovascular risk factor (29.2%) followed by diabetes (6.1%). Previous history of heart failure accounted for 0.5%, whereas
previous cardiac disease was identiﬁed in 6.3% of population.
Conclusion The changes of the original protocol of the COT Registry and ﬁrst update allow a ﬁrst glance to the panorama of
cardiovascular characteristics of breast cancer patients enrolled.
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The need for a registry on drug-related
cardiotoxicity in breast cancer patients
In relation with important advances in adjuvant therapy
drugs (anthracyclines, taxanes, and trastuzumab), both
disease-free survival and mortality rates of cancer patients
have been substantially improved in the last decade.1 In
parallel, the increased survival has brought the problem of
anticancer drug-related cardiotoxicity (ADRC) to the attention
of both oncologists and cardiologists.2,3 The European Society
of Cardiology (ESC) timely created a task force for cancer
treatments and cardiovascular toxicity, which has published
in August 2016 a comprehensive position paper on this issue,
under the auspices of the ESC Committee for Practice
Guidelines.4
In this context, breast cancer-related ADRC, the most
common cancer in women,1 is gaining increasing impact.
Age-adjusted 5 year survival of breast cancer patients is
known to be about 79%.4 A variable proportion of these
patients experience ADRC, which can develop during/after
anthracycline therapy (cardiotoxicity type 1) or be related
to the use of humanized monoclonal antibodies against
extracellular domain of HER2, such as trastuzumab
(cardiotoxicity type 2).5 These two kinds of cardiotoxicity
may overlap in breast cancer patients, as these two different
classes of drugs are usually administered sequentially.
Worthy of note, trastuzumab has shown to have a synergic
effect on anthracycline’s cardiotoxicity.6
To date, the poor data available on presentation and
management of breast cancer patients with ADRC are mainly
provided by clinical trials, which do not reﬂect the real world.
In addition, information on cardiac imaging and biomarker
practice for the detection and follow-up of ADRC into clinical
routine in Europe is limited.
Main objectives of the Cardiac
Oncology Toxicity Registry
European Association of Cardiovascular Imaging/Heart
Failure Association Cardiac Oncology Toxicity (COT) Registry
was launched as a multicentre registry, part of the
EURObservational Research Programme of the ESC of
patients affected by breast cancer referred to imaging
laboratories for routine surveillance, suspicion, or
conﬁrmation of ADRC. It concerns a comprehensive data
collection and evaluation of the current European practice
in terms of diagnosis and management of ADRC in breast
cancer patients. The COT Registry has been designed to
examine clinical signs and symptoms as well as cardiac
imaging and treatment practices for ADRC in breast cancer
patients in Europe. The cardiac imaging exam actually
provides an opportunity to collect clinical information and
detects the onset, progression, or resolution of ADRC. The
imaging evaluation concerns mainly an echo exam, which is
periodically repeated, including the assessment of standard
parameters such as left ventricular (LV) ejection fraction,
Doppler-derived diastolic parameters (E/A ratio, E velocity
deceleration time, and E/e0 ratio), left atrial volume and,
optionally, global longitudinal strain according to American
Society of Echocardiography/European Association of
Cardiovascular Imaging Expert Consensus for Multi-Modality
Imaging Evaluation of Adult Patients During and After Cancer
Therapy.7
The main scopes of the COT Registry include the following:
(i) deﬁnition of ADRC-related risk factors, clinical phenotypes,
and epidemiology; (ii) determination of ADRC outcomes; (iii)
report of asymptomatic/symptomatic ADRC rates; (iv)
description of ADRC time course; (v) recording of current
standards for diagnostic workup (cardiac imaging/
biomarkers) and clinical follow-up of those patients; (vi)
assessment of treatment changes associated with ADRC and
their inﬂuence on ADRC; (vii) description of cardioprotective
drugs and other therapeutic approaches used for ADRC; and
(viii) evaluation of treatment adherence to ESC Guidelines
for overt heart failure (HF) or early asymptomatic LV
dysfunction.8 Rationale and scopes of the COT Registry have
been previously published.9
Changes from the Cardiac Oncology
Toxicity protocol ﬁrst release
The COT Registry was launched in October 2014 and will last
until December 2017 or until 3000 patients are included.
After passing through a ﬁrst short-term pilot phase (1 year
recruitment and 1 year follow-up), some changes have been
made to the protocol and the electronic case report form
(CRF) in order to improve data quality and allow a better
analysis of the results. The main protocol changes of the
version 2.0 dated 1 October 2015 concerned:
• exclusion/inclusion criteria,
• duration of the registry and study sample size, and
• clariﬁcation on the deﬁnition of the study population.
The exclusion criterion of isolated breast cancer
radiotherapy has been removed, so that the only exclusion
concerns the history of a pre-chemotherapy LV dysfunction
(LV ejection fraction <50%).
The period for long-term registry recruitment has been
reduced (December 2017 instead of June 2018), but the target
study population has been extended to 3000 breast cancer
patients instead of 700 ADRC, initially established in the
protocol version 1.0. The Executive Committee with the
approval of the Oversight Committee of the EURObservational
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Research Programme has reserved the chance to continue the
registry going further the declared deadline.
Version 2.0 of the protocol better deﬁnes the
characteristics of the study population. Breast cancer patients
seen in an imaging lab (echo or nuclear cardiology) for
routine surveillance of LV function or suspected ADRC or
conﬁrmed LV dysfunction are enrolled in the registry.
Following these criteria, the study population will include
patients undergoing chemotherapy with associated targeted
therapy (e.g. trastuzumab) or no targeted therapy, at
increased risk of ADRC.
The outpatients’ visits are performed according to the
usual practice of the participating centres as established in
the version 1.0. However, the 1 month follow-up visit has
been abolished in order to introduce in the protocol a
scheduled 3 month follow-up visit after enrolment, which
reﬂects the common clinical practice in European imaging
laboratories. Accordingly, data on morbidity and mortality
at 3, 6, and 12 months after the entry visit will be collected.
Table 1. List of active contributing countries
Country
Baseline
Enrolled patients (%) Locked CRFs
Austria 10 0.8 7
Belgium 132 10.2 76
China 9 0.7 0
Cyprus 11 0.9 2
France 34 2.6 0
Georgia 12 0.9 11
Germany 28 2.2 17
Greece 38 2.9 29
Italy 662 51.2 481
Malta 19 1.5 10
The Netherlands 1 0.1 0
Norway 13 1.0 9
Portugal 85 6.6 63
Romania 68 5.3 46
Saudi Arabia 99 7.7 16
Serbia 50 3.9 0
Spain 23 1.8 16
Total 1294 100.0 783
CRFs, case report forms.
Figure 1 Percentage of patients on anticancer drug therapy (upper panel) and of those on anticancer targeted therapy (ongoing or completed) in
breast cancer patients of the Cardiac Oncology Toxicity Registry (lower panel).
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Information on recruitment and
preliminary results
The ﬁrst patient visit of the COT Registry occurred in October
2014. In 27 registered countries, 110 centres were registered
in Europe and countries outside Europe such as Argentina,
Brazil, Saudi Arabia, China, and India. Among these, 17 countries
Table 2. Population synthesis regarding ADRC in the Cardiac
Oncology Toxicity Registry
Type of ADRC n %
Surveillance of LV function 725 92.6
Conﬁrmed diagnosis of ADRC 35 4.47
Suspected diagnosis of ADRC 23 2.9
Total 783 100.0
ADRC, anticancer drug-related cardiotoxicity; LV, left ventricular.
Figure 2 Prevalence of arterial hypertension, diabetes mellitus, smoking status, dyslipidemia, history of heart failure, and previous cardiac disease in
the initial population of the Cardiac Oncology Toxicity Registry. The term ‘unknown’ refers to patients in whom the speciﬁc information was not
collected.
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(68%) and 58 centres (53%) are actually active. The leading
enrolling countries are Italy (51.2%) followed by Belgium
(10.2%), Saudi Arabia (7.7%), Portugal (6.6%), and
Romania (5.3%). Globally, 1294 breast cancer patients have
been enrolled, and 783 CRFs locked (CRF can be locked when
all oncologic and cardiologic parameters are collected for
individual patients) making possible a preliminary analysis of
the results (Table 1).
Of these 783 patients, 481 (61.4%) were seen at their ﬁrst
evaluation, that is, referred to the cardiac imaging lab for a
baseline (pre-anticancer drug therapy) evaluation, whereas
302 (38.6%) were already on oncologic treatment with
anticancer drug therapy; in this latter group, 52 patients
(17.2%) were not in targeted therapies (mainly
anthracyclines), 191 (63.3%) were ongoing targeted therapy,
and 59 (19.5%) had completed it (Figure 1). Table 2
summarizes the hitherto population synthesis regarding
the detected ADRC in the COT Registry: 23 (2.9%) patients
had a suspected and 35 (4.5%) a conﬁrmed diagnosis of
ADRC. In the overall population, arterial hypertension was
the most prevalent cardiovascular risk factor (29.2%)
followed by diabetes mellitus (6.5%), whereas smoking
status (13.4%) and dyslipidemia (24.3%) appeared rarely.
Previous history of HF (before the beginning of anticancer
drug therapy) accounted for 0.5%, whereas previous
cardiac disease was identiﬁed in 6.3% of the study
population (Figure 2).
Implications
Changes of electronic CRF in version 2.0 of the COT Registry
were performed to improve the data collection and provide
the possibility of more comprehensive analyses and better
interpretation of the results. In particular, these changes
reﬂect more appropriately the common clinical practice in
European countries. The inclusion of patients undergoing
isolated breast cancer radiotherapy enlarges the sample size
of the study population, again being much more
representative of the breast cancer population in the real
world. Radiotherapy is in fact often associated with drug
therapy in the management of these patients. The main
effects of radiotherapy-induced toxicity involve vascular
system (coronary and carotid arteries), myocardium itself,
pericardium, heart valves, and conduction system, leading
to possible multiple clinical aspects of cardiac damage, mainly
coronary artery disease, HF, and arrhythmias.10–13
The analysis of preliminary results highlights the type and
rate of ADRC as well as the prevalence of cardiovascular risk
factors in the study population.
The combined rate of suspected and conﬁrmed ADRC
was 7.4%, a rate that should not be under evaluated. This
ﬁnding is valuable as it has been derived by real-world
evidence. This is actually an important advantage of a
registry in comparison with clinical trials. Data derived from
clinical trials are expected to underestimate the ‘true’
frequency of HF in cancer patients for two main reasons:
ﬁrst, patients at risk of HF based on previous cardiac diseases
are excluded; second, cancer trial participants who
developed HF symptoms could drop out of chemotherapy
trials without undergoing follow-up. Even in epidemiologic
studies, HF due to ADRC may be underestimated because
of the long interval between chemotherapy and clinical
ﬁndings.
Other important data involve the prevalence of
cardiovascular risk factors observed in the study population
of COT Registry. The relatively high rate of arterial
hypertension (29.3%) combined with the 24% rate of
dyslipidemia and 5% rate of diabetes mellitus points out a
possible common denominator of metabolic syndrome and
cancer. This association has already been reported,14 as
insulin resistance is associated with HF.15 Arterial
hypertension has previously been identiﬁed as one of the
main factors for ADRC.16,17 The rate of previous cardiac
disease was 6.3%, another ﬁnding, which conﬁrms previous
investigations.16 The increasing number of the COT study
population might inﬂuence the determinants of ADRC
because of factors such as age, previous cardiac irradiation,
and especially coronary artery disease.
In conclusion, changes of the original protocol of the COT
Registry and ﬁrst update allow a ﬁrst glance to the panorama
of cardiovascular characteristics of breast cancer patients
enrolled. A larger population will be needed to provide
information on outcome of ADRC, to describe the time
course of ADRC according to the beginning of chemotherapy,
and to design the exact picture of the European standards
for diagnostic workup and clinical follow-up of these
patients as well as the treatment adherence to ESC
Guidelines for overt and asymptomatic HF. Worthy of note,
ﬁnal release and completion of the COT Registry will
represent a possible model to collect cardiac information
on diagnosis and management of ADRC in other types of
tumours.
Acknowledgements
The EACVI/HFA thanks the EORP staff at the Heart House
for their support. Registry Executive Committee of the
EURObservational Research Programme (EORP). Data collection
was conducted by the EORP department from the ESC by Rachid
Mir Hassaine as Clinical Project Manager, Katell Lemaitre as
Project Ofﬁcer, Maryna Andarala as Data Manager and
Statistican. Overall activities were coordinated and supervised
by Doctor Aldo P. Maggioni (EORP Scientiﬁc Coordinator). All
investigators listed in Supporting Information Appendix S1.
316 P. Lancellotti et al.
ESC Heart Failure 2017; 4: 312–318
DOI: 10.1002/ehf2.12162
Executive Committee
EACVI: Patrizio Lancellotti (Chair), Erwan Donal, Thor Edvardsen,
Maurizio Galderisi, Gilbert Habib, Bogdan A. Popescu,
Chiara Lestuzzi






The ESC-COT Registry will be funded by the ESC. Since the
start of EORP, the following companies have supported the
programme: Abbott Vascular Int. (2011–2014), Amgen
Cardiovascular (2009–2018), AstraZeneca (2014–2017), Bayer
AG (2009–2018), Boehringer Ingelheim (2009–2019), Boston
Scientiﬁc (2009–2012), The Bristol Myers Squibb and Pﬁzer
Alliance (2011–2016), The Alliance Daiichi Sankyo Europe
GmbH and Eli Lilly and Company (2011–2017), Edwards
(2016–2019), Gedeon Richter Plc. (2014–2017), Menarini
Int. Op. (2009–2012), MSD-Merck & Co. (2011–2014),
Novartis Pharma AG (2014–2017), ResMed (2014–2016),
Sanoﬁ (2009–2011), and SERVIER (2009–2018).
Supporting information
Supporting information may be found in the online version of
this article.
Appendix S1. Executive Committee, EORP Team and
Investigators.
References
1. Ferlay J, Steliarova-Foucher E, Lortet-
Tieulent J, Rosso S, Coebergh JW,
Comber H, Forman D, Bray F. Cancer
incidence and mortality patterns in
Europe: estimates for 40 countries in
2012. Eur J Cancer 2013; 49:
1374–1403.
2. Murbraech K, Solheim O, Aulie HM,
Fossa SD, Aakhus S. The impact of
cisplatinum-based chemotherapy on
ventricular function and cardiovascular
risk factors in female survivors after
malignant germ cell cancer. Expecting
the unexpected: right atrial mass in a
transplant patient. ESC Heart Fail 2015;
2: 142–149.
3. Akpek M, Ozdogru I, Sahin O, Inanc M,
Dogan A, Yazici C, Berk V, Karaca H,
Kalay N, Oguzhan A, Ergin A. Protective
effects of spironolactone against
anthracycline-induced cardiomyopathy.
Eur J Heart Fail 2015; 17: 81–89.
4. Zamorano JL, Lancellotti P, Rodriguez
Muñoz D, Aboyans V, Asteggiano R,
Galderisi M, Habib G, Lenihan DJ, Lip
GY, Lyon AR, Lopez Fernandez T, Mohty
D, Piepoli MF, Tamargo J, Torbicki A,
Suter TM, Authors/Task Force Members.;
ESC Committee for Practice Guidelines
(CPG): The Task Force for cancer
treatments and cardiovascular toxicity of
the European Society of Cardiology
(ESC). 2016 ESC Position Paper on cancer
treatments and cardiovascular toxicity
developed under the auspices of the
ESC Committee for Practice Guidelines.
Eur Heart J 2016; 37: 2768–2801.
5. Verdecchia A, Francisci A, Brenner H,
Gatta G, Micheli A, Mangone L, Kunkler
I, EUROCARE-4 Working Group. Recent
cancer survival in Europe: a 2000–02
period analysis of EUROCARE-4 data.
Lancet Oncol 2007; 8: 784–796.
6. Brower V. Cardiotoxicity debated for
anthracyclines and trastuzumab in
breast cancer. J Natl Cancer Inst 2013;
105: 835–836.
7. Slamon D, Eiermann W, Robert N,
Pienkowski T, Martin M, Press M,
Mackey J, Glaspy J, Chan A, Pawlicki
M, Pinter T, Valero V, Liu MC, Sauter G,
von Minckwitz G, Visco F, Bee V, Buyse
M, Bendahmane B, Tabah-Fisch I,
Lindsay MA, Riva A, Crown J, Breast
Cancer International Research Group.
Adjuvant trastuzumab in HER2-positive
breast cancer. N Engl J Med 2011; 365:
1273–1283.
8. Ponikowski P, Voors AA, Anker SD,
Bueno H, Cleland JG, Coats AJ, Falk
V, González-Juanatey JR, Harjola VP,
Jankowska EA, Jessup M, Linde C,
Nihoyannopoulos P, Parissis JT, Pieske
B, Riley JP, Rosano GM, Ruilope LM,
Ruschitzka F, Rutten FH, van der
Meer P, Authors/Task Force Members.
2016 ESC Guidelines for the diagnosis
and treatment of acute and chronic
heart failure: The Task Force for the
diagnosis and treatment of acute and
chronic heart failure of the European
Society of Cardiology (ESC) developed
with the special contribution of the
Heart Failure Association (HFA) of
the ESC. Eur Heart J 2016; 37:
2129–2200.
9. Lancellotti P, Anker SD, Donal E,
Edvardsen T, Popescu BA, Farmakis
D, Filippatos G, Habib G, Maggioni
AP, Jerusalem G, Galderisi M. EACVI/
HFA Cardiac Oncology Toxicity Registry
in breast cancer patients: rationale,
study design, and methodology (EACVI/
HFA COT Registry)—EURObservational
Research Program of the European
Society of Cardiology. Eur Heart
J Cardiovasc Imaging 2015; 16:
466–470.
10. Plana JC, Galderisi M, Barac A, EwerMS,
Ky B, Scherrer-Crosbie M, Ganame J,
Sebag IA, Agler DA, Badano LP, Banchs
J, Cardinale D, Caver J, Cerqueira M,
De Cara JM, Edvarsen T, Flamm SD,
Force T, Grifﬁn BP, Jerusalem G, Liu JE,
Magalhães A, Marwick T, Sanchez LY,
Sicari R, Villarraga HR, Lancellotti P.
Expert consensus for multi-modality
imaging evaluation of adult patients
during and after cancer therapy: a
report from the American Society of
Echocardiography and the European
Association of Cardiovascular Imaging.
Eur Heart J Cardiovasc Imaging 2014;
15: 1063–1093.
11. Darby SC, Ewertz M, Hall P. Ischemic
heart disease after breast cancer
radiotherapy. N Engl J Med 2013; 368:
2523–2527.
12. Shapiro C, Hardenbergh P, Gelman R,
Blanks D, Hauptman P, Recht A, Hayes
DF, Harris J, Henderson IC. Cardiac
effects of adjuvant doxorubicin and
radiation therapy in breast cancer
patients. J Clin Oncol 1998; 16:
3493–3951.
13. Hooning M, Botma A, Aleman B,
Baaijens M, Bartelink H, Klijn J, Taylor
COT Registry: protocol update and preliminary results 317
ESC Heart Failure 2017; 4: 312–318
DOI: 10.1002/ehf2.12162
CW, van Leeuween FE. Long-term risk
of cardiovascular disease in 10-year
survivors of breast cancer. J Natl Cancer
Inst 2007; 99: 365–375.
14. Agnoli C, Grioni S, Sieri S, Sacerdote C,
Ricceri F, Tumino R, Frasca G, Pala V,
Mattiello A, Chiodini P, Iacoviello L, De
Curtis A, Panico S, Krogh V. Metabolic
syndrome and breast cancer risk: a
case-cohort study nested in a
multicentre Italian cohort. PLoS One
2015; 10: e0128891.
15. Doehner W, Turhan G, Leyva F,
Rauchhaus M, Sandek A, Jankowska
EA, von Haehling S, Anker SD. Skeletal
muscle weakness is related to insulin
resistance in patients with chronic
heart failure. ESC Heart Fail 2015; 2:
85–89.
16. Bhave M, Shah AN, Akhter N, Rosen ST.
An update on the risk prediction and
prevention of anticancer therapy-
induced cardiotoxicity. Curr Opin Oncol
2014; 26: 590–599.
17. Russo G, Ciofﬁ G, Gori S, Tuccia F,
Boccardi L, Khoury G, Lestuzzi C,
Maurea N, Oliva S, Faggiano P, Tarantini
L, ICARO (Italian CARdio-Oncological)
Network. Role of hypertension on new
onset congestive heart failure in patients
receiving trastuzumab therapy for breast
cancer. J Cardiovasc Med 2014; 15:
141–146.
318 P. Lancellotti et al.
ESC Heart Failure 2017; 4: 312–318
DOI: 10.1002/ehf2.12162
